YOU ARE HERE: LAT HomeCollections

Birth control pill concerns bring lawsuits but few solid answers

Yaz and Yasmin complaints focus on the synthetic progestin, drospirenone. Studies have not found an increased risk with these pills, though.

April 19, 2010|By Tammy Worth | Special to the Los Angeles Times
(Jim Sulley / Newscast )

When the oral contraceptives Yasmin and Yaz came on the market in 2001 and 2006, respectively, they were thought to be safer than other birth control pills because they contained a different kind of synthetic progestin.

But in a flurry of lawsuits against the pills' maker, Bayer HealthCare, attorneys claim that the progestin contained in the pills, drospirenone, is the cause of health problems, including deep vein thrombosis (blood clots in the deep veins), strokes, heart attacks and gallbladder disease.

As of mid-February, about 1,100 lawsuits had been filed in the United States against Bayer, which stands behind the safety of the pills.

Research on the issue is divided. Some studies have found drospirenone to pose no greater health risk than other birth control pills; some studies show a sixfold greater risk of getting blood clots, even in young, healthy women. More research is being performed on the safety of the contraceptives, but for now, women considering taking the pills will need to weigh the contradictory information themselves.

"There is reason to be concerned, I believe, about both of them [Yaz and Yasmin]," said Dr. Sidney Wolfe, founder and director of Public Citizen's Health Research Group, a nonprofit advocacy organization based in Washington, D.C. "When evidence like that comes up, people should pay attention to it."

Oral contraceptives control unwanted pregnancies by using hormones that block ovulation. The first of these pills, introduced in the United States in the early 1960s, contained high doses of estrogen. They were quickly found to raise the risk of stroke, blood clots and heart attacks.

Second-generation pills introduced in the 1970s contained lower amounts of estrogen combined with synthetic progestins, including one called levonorgestrel. These reduced the risk of blood clots but caused side effects such as weight gain and acne in many women.

The 1980s brought third-generation pills containing different synthetic progestins, such as one called desogestrel. These were later found to be associated with a higher risk of deep vein thrombosis and pulmonary embolism.

The fourth-generation pills — Yaz, Yasmin and Ocella, a generic version — contain estrogen and yet another progestin, drospirenone. They were created not just to prevent pregnancy but to also reduce the side effects of previous pills and to treat premenstrual dysphoric disorder (severe cases of depression, anxiety, headaches and other symptoms).

Yaz is now the No. 1-selling birth control in the United States, grossing more than $391 million in the first half of 2009, up 44% from the same time period in 2008, according to health data provider IMS Health. Bayer received a warning from the FDA last year for overstating Yaz's effectiveness in treating PMDD and acne while minimizing the risks of the medication on its website and television commercials. In response, the company altered its advertising.

Now the contraceptives are not just the subject of lawsuits, they're also under scrutiny by groups such as Public Citizen over their safety. The FDA is testing the safety of Yaz and other pills in an ongoing study.

Two 2009 reports helped raise alarms. Published in the British Medical Journal, both assessed whether drospirenone is more likely to cause blood clots than other types of synthetic progestins.

One study looked at blood clot rates in Danish women ages 15 to 49 with no history of cardiovascular disease. From 1995 to 2005, there were 4,213 cases of various kinds of blood clots including in the heart, kidney, lungs and liver, 2,045 of which occurred in users of oral contraceptives. Researchers found that pills containing the progestins desogestrel, gestodone and drospirenone (the one found in Yasmin, Yaz and Ocella) were associated with a higher risk of blood clots than those containing levonorgestrel.

A second studied more than 3,200 women from the Netherlands. In this case, participants taking birth control pills containing levonorgestrel had a four times higher risk of getting blood clots than women taking no birth control, and for other progestins the risk was higher still: 5.6 times greater for gestodone, 6.3 times greater for drospirenone and 7.3 times greater for desogestrel. The greatest risk occurred during the first three months of oral contraceptive use.

"It clearly concludes that the safest thing to do is take the older [birth control pills], not the third generation or Yaz," Wolfe said.

Public Citizen had already placed Yasmin on its "Do Not Use" list because it can raise blood potassium levels, Wolfe added.

Rose Talarico, deputy director of external product communications for Bayer, said in an e-mail that Bayer "will defend itself vigorously against these lawsuits" and that patient safety is important to the company. She said the company's drospirenone-containing oral contraceptives "are safe and effective when used according to the product labeling."

Los Angeles Times Articles